Pathway analysis

Genomics Market to Reach $94.86 Billion by 2030 at CAGR 16.5%: Grand View Research, Inc.

Retrieved on: 
Wednesday, April 19, 2023
Metagenomics, Survivor, CRISPR, Molecular epidemiology, Chromosome, Therapy, SARS-CoV-2, Genomics, National Centre for Disease Control, University of Cambridge, NGS, IHOP, National Cancer Institute, Pathway analysis, Inherited disorders of trafficking, Research, Genetic Alliance, Infection, OGL, DSM-IV codes, Biomarker, USD, Government, CDC, Whole genome sequencing, Revenue, Nature, SAN, Biomarker discovery, Functional genomics, Cancer, Merck & Co., Rare, Gene, Genetic disorder, Disease, Illumina, Inc., Antibiotics, Vaccine, Epigenomics

SAN FRANCISCO, April 19, 2023 /PRNewswire/ -- The global genomics market size is expected to reach USD 94.86 billion by 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, April 19, 2023 /PRNewswire/ -- The global genomics market size is expected to reach USD 94.86 billion by 2030, according to a new report by Grand View Research, Inc.
  • The market is expected to register a CAGR of 16.5% in the forecast period owing to the increasing demand for novel therapeutic and research applications in genomics.
  • Read full market research report more latest industry insights, " Genomics Market Size, Share & Trends Analysis Report By Technology & Application (Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery), By Deliverables, End-use, By Region, And Segment Forecasts, 2023 - 2030 ", published by Grand View Research.
  • Grand View Research has segmented the global genomics market on the basis of application, deliverables, end-use, and region
    Genomics Market - Application & Technology Outlook (Revenue, USD Million, 2018 - 2030)

Genomics Global Market Report 2022: Increasing Demand for Novel Therapeutics Drives Sector - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 24, 2022
Biotechnology, Genetics, Health, Genetic Alliance, Genetic disorder, Genomics, Molecular epidemiology, Infection, IHOP, Government, CDC, Cancer, Severe acute respiratory syndrome coronavirus 2, National Cancer Institute, University of Cambridge, Survivor, Biomarker, Functional genomics, USD, Biomarker discovery, Research, CRISPR, Pathway analysis, Nature, Chromosome, Metagenomics, National Centre for Disease Control, Disease, Whole genome sequencing, Therapy, Degenerative disease, Inherited disorders of trafficking, NGS, Illumina, Inc., Merck & Co., OGL, Gene, Antibiotics, Epigenomics

The "Genomics Market Size, Share & Trends Analysis Report by Technology & Application (Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery), by Deliverables, End Use, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genomics Market Size, Share & Trends Analysis Report by Technology & Application (Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery), by Deliverables, End Use, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global genomics market size is expected to reach USD 94.9 billion by 2030.
  • The market is expected to register a CAGR of 16.4% in the forecast period owing to the increasing demand for novel therapeutics and research applications in genomics.
  • Functional genomics held the largest market share in the year 2021, owing to the demand for rising applications in diagnostics and gene therapy.

Global Genomics Market Research Report 2021: Focus on Functional Genomics & Pathway Analysis - Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 14, 2021
Health, Genetics, Degenerative disease, Technology, Diabetes, Product, Severe acute respiratory syndrome coronavirus 2, CGH, Genome, Solution, Awareness, Cepheid variable, Biomedical Research, Gene, Adoption, Lists of diseases, Cancer, Breast cancer, Cepheid (company), Veritas Genetics, Academic health science centre, Efficiency, Data management, DNA, Karyotype, Patient, PCR, 23andMe, Functional genomics, COG-UK, NGS, COVID-19 Genomics UK Consortium, Biotechnology, Pathway analysis, Prognosis, Quest Diagnostics, COVID-19, Application, Genomics, Asia-Pacific, Thermo Fisher Scientific, Catalog, Consortium, Antibiotics, Vaccine, Animal

The "Global Genomics Market Size, Share & Trends Analysis Report by Application & Technology (Functional Genomics, Pathway Analysis), by Deliverable (Products, Services), by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Genomics Market Size, Share & Trends Analysis Report by Application & Technology (Functional Genomics, Pathway Analysis), by Deliverable (Products, Services), by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • This has also led to an increase in the market competition, coupled with the development of breakthrough genomic technologies by Veritas Genetics, 23andMe, and other key players.
  • In August 2020, Ancestry launched a new next-generation sequencing-based tool to screen genes linked to blood disorders, colon cancer, heart diseases, and breast cancer.
  • This product, developed by Quest Diagnostics, has a better DNA analysis efficiency when compared to microarray-based testing.

Canopy Biosciences launches interactive data analysis partnership with OnRamp BioInformatics™

Retrieved on: 
Tuesday, June 16, 2020
Branches of biology, Biology, Molecular biology, Genomics, RNA, Multiomics, Bioinformatics, RNA-Seq, Omics, Pathway analysis, Gene expression, Qlucore

ST. LOUIS, June 16, 2020 /PRNewswire/ -- Canopy Biosciences, a multi-omic CRO providing NanoString nCounter and RNA Seq services to both clinical and research customers, has partnered with OnRamp BioInformatics to offer their ROSALIND interactive data analysis platform for Canopy's gene expression services.

Key Points: 
  • ST. LOUIS, June 16, 2020 /PRNewswire/ -- Canopy Biosciences, a multi-omic CRO providing NanoString nCounter and RNA Seq services to both clinical and research customers, has partnered with OnRamp BioInformatics to offer their ROSALIND interactive data analysis platform for Canopy's gene expression services.
  • The ROSALIND platform enables customers to view differential gene expression data from NanoString and RNA Seq experiments in an interactive interface, providing figures and pathway analysis enabling collaboration with teams across the globe.
  • Canopy's expertise in running these platforms and interpreting complex data, combined with ROSALIND's visualization, will give customers a decision-empowering data package even those customers without dedicated bioinformatics capabilities.
  • As part of their broader platform for multi-omics data analysis, Canopy has replaced their legacy comprehensive data analysis report with the ROSALIND offering.